ArticleF1000Research2020

Augmented ustekinumab dosing is needed to achieve clinical response in patients with anti-TNF refractory pediatric Crohn's disease: a retrospective chart review.

Phinga Do et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.